Cytel Inc. builds the statistical infrastructure behind drug development. Founded in 1987 by research scientists from Harvard and MIT, the company designs clinical trials for biotech and pharmaceutical companies using advanced analytics and Bayesian methods - essentially trying to make trial-and-error less error-prone. Their core threat model isn't external attackers but statistical failure: poorly designed trials that waste years and billions while patients wait. The team, over 2,000 people, operates across Cambridge, London, Paris, and Pune, working at the intersection of statistics, data science, and software development.
The technical stack centers on proprietary platforms - East Horizon, StatXact, and Solara - that have been used in thousands of trials worldwide. These tools handle adaptive trial designs, direct study design, and data analysis. The engineering culture is rooted in quantitative rigor, with statisticians and software developers collaborating on problems where getting the math wrong has real human consequences. Cytel has been in this domain for nearly four decades, building credibility through sustained technical work in Bayesian methods and clinical trial design.
For security professionals, the stakes are clear: Cytel's systems process sensitive clinical trial data for the pharmaceutical industry. Healthcare and pharmaceutical data carries regulatory obligations (HIPAA, GDPR, GxP compliance) and attracts targeted threat actors interested in proprietary drug development data. The company's global footprint across four countries means security operations must account for cross-border data flows, multiple regulatory regimes, and the protection of statistical models and software platforms that are central to their clients' drug pipelines.